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INTRODUCTION
Widespread uptake of potent antiretroviral therapy (ART) holds the promise of reducing HIV morbidity and transmission, but it requires consistent engagement with the healthcare system. Although the success of efforts to identify HIV-infected individuals and retain them in care is remarkable -12.9 million people were receiving ART worldwide at the end of 2013 and AIDS-related deaths have fallen by 35% since 2005, efforts continue to fall short of the growing epidemic. It is estimated that 2.1 million people were newly infected with HIV in 2013, and that of the 35 million people living with HIV (PLHIV) in the world, 22 million are not accessing treatment [1] .
There has been increasing focus on the importance of maintaining PLHIV in the HIV treatment and care cascade, highlighted by the recent establishment of UNAIDS 90-90-90 Fast Track targets (90% of PLHIV knowing their HIV status, 90% of those knowing their HIV status on treatment, and 90% of those on HIV treatment virally suppressed) [2] . Within the HIV care cascade, there are several stages at which to engage patients and HIV care providers: HIV testing and diagnosis, linkage to HIV care, retention in HIV care, ART prescription, and achieving virologic suppression. For the purposes of our review, we have grouped linkage to and retention in care together, as well as grouping prescription of and adherence to ART with virologic suppression.
Successful maintenance of patients through the cascade varies. Although 86% of PLHIV in the United States are diagnosed, only 40% of PLHIV are engaged in care, 37% prescribed ART, and 30% virally suppressed [3] . In Rwanda, it is estimated that 63% of PLHIV are on ART and 52% virally suppressed [4] , higher than the prevalence of virologic suppression in the United States and in British Columbia [5] . Substantial improvement is needed along the cascade to reach the UNAIDS Fast Track goals.
Increasingly, attention has turned to the field of behavioral economics to help improve patient engagement in HIV care and prevention by augmenting more traditional behavioral interventions. Although the bulk of previous work, and therefore reviews of this topic, has focused on financial incentives for HIV prevention [6] [7] [8] [9] , emerging data relate to financial incentives as a means of promoting HIV testing, linkage to care, and adherence to treatment. Financial incentives may be used to, first, explicitly address structural risk factors for HIV, such as payments to relieve poverty or increase education; these programs pay households for a child that attends school, or second, provide conditional rewards for immediate, measureable outcomes related to HIV, such as cash for attending a first clinic visit after HIV diagnosis; these are more akin to contingency management [9] .
In this review, we focus on both conditional and unconditional financial incentives that have been assessed for their impact on the HIV care cascade through randomized controlled trials, observational studies, or government social protection programs. We provide a brief background on the rationale for using financial incentives to improve health outcomes, review recent (assessed through a PubMed search of terms such as 'HIV incentive', 'HIV cash', and 'HIV cash transfer') and ongoing studies (assessed through clinicaltrials.gov) using incentives for steps in the HIV care cascade, and outline key considerations for future work.
RATIONALE FOR FINANCIAL INCENTIVES IN HIV CARE CASCADE
Behavioral economics integrates psychological and economic principles to understand individual decision making [8] . In contrast to traditional microeconomic theory, behavioral economics recognizes that decisions are not consistently rational, and are strongly influenced by contextual factors, beliefs, competing demands, emotion, and other social-cognitive factors [8] . Specifically, individuals often make a 'rational' choice to pursue unhealthy behaviors over healthy behaviors, which are often associated with a delay and uncertainty in anticipated health gains (i.e., reduced disease risk in the future) and immediate and certain financial and opportunity costs (i.e., giving up leisure time to attend clinic visits) [10 & ]. Within this context of rewards based on time and certainty, it is hypothesized that health-promoting financial incentives would be attractive to individuals and influence health decision making, as they provide certain and near-immediate reward for health-promoting behaviors. Incentives can also potentially increase use of health services by offsetting real costs that may come from seeking healthcare, such as those of travel or missed work. [11] . Effective financial incentives employ basic principles of behavior reinforcement, including identification of target behavior, frequent collection of an objective measure of that behavior, selection of desirable reinforcement, and consistent and immediate link between target behavior and reinforcers [12] . Conditional incentive-based approaches have been successfully used in multiple settings to promote healthy behaviors, including smoking cessation, weight loss, adherence to childhood vaccination, and antenatal clinic visits [13] [14] [15] [16] [17] .
These concepts can easily be applied to the HIV care cascade. For example, people may not adhere to ART because they perceive a reduction in utility because of out-of-pocket costs, side-effects, and
KEY POINTS
Behavioral economics can help improve engagement in HIV care by explicitly addressing structural risk factors for HIV such as poverty, or providing conditional rewards for immediate, measurable outcomes related to HIV care.
Observational studies and one randomized study support the use of incentives for improving uptake of HIV testing and HIV test result receipt.
Several small USA-based studies have shown an impact of financial incentives on ART adherence, but have not had durable results beyond the end of the incentive period.
Promising examples for the HIV care cascade come from HIV prevention in adolescents and young adults, in whom both conditional incentives delivered through research studies and unconditional governmentadministered social protection grants have been shown to decrease high-risk sexual behavior.
Understanding the efficacy, durability, scalability, and cost-effectiveness of different approaches to using incentives will be critical for maximizing their impact in curtailing the HIV epidemic.
delayed benefits. Although they may know that poor adherence can lead to treatment failure, opportunistic infections, and HIV transmission, these events may occur far into the future. People-prescribed ART may discount the future and prefer the current utility of not adhering over future benefits of controlled viral load. Hence, conditional incentives help bring forward in time the benefits of treatment, for example, increasing income when adherent to ART and making specific costs (i.e., losing incentives) more salient [6, 18] .
HIV TESTING
HIV testing and diagnosis is the first stage in the HIV treatment and care cascade in which financial incentives can be used to increase uptake of services. To date, five studies have investigated how financial incentives can be used in this context ( Table 1) .
The earliest published work on using incentives in the HIV care cascade focused on HIV testing. This single US-based study targeted and prospectively enrolled emergency department patients in Los Angeles deemed at high risk for HIV based on Centers for Disease Control and Prevention criteria [19] . All participants during the 18-month study were referred for on-site HIV counseling and testing, but only those during the second 6-month period received $25 for completing HIV counseling and testing within 1 week. During the control periods, 20 (8%) of 252 patients reached the study outcome, completion of HIV counseling and testing, compared with 27 (23%) of 120 participants that were financially incentivized during the intervention period [odds ratio 3.4, 95% confidence interval (CI) 1.8-6.3].
Other studies incentivizing HIV testing were carried out at nonclinical sites in sub-Saharan Africa. Thornton [20] performed a randomized trial in which nearly 3000 participants in rural Malawi were offered free door-to-door HIV testing and randomly assigned vouchers of US$0-3, redeemable upon obtaining their test results at a nearby voluntary counseling and testing center. The demand for test results among those who received no incentive was 34%; those who received a voucher of any value were twice as likely to go to the center to retrieve their results compared with individuals receiving no incentive, controlling for distance. Furthermore, there was a positive linear effect on outcome with the level of incentive; each extra dollar increased collection of test results by 9%. Of note, the number of US$0 incentives distributed was less than that anticipated by chance, which speaks to the difficulty of delivering incentives equitably in the field. Two Cape Town-based studies targeted incentivized testing to high-risk groups with traditionally lower HIV testing uptake: men and adolescents. Nglazi et al. [21] performed a retrospective analysis among over 9000 men accessing incentivized and nonincentivized mobile rapid HIV testing services compared with clinic-based testing services in underserved periurban areas of Cape Town, South Africa. Participants who underwent incentivized testing received a food voucher worth US10 redeemable at local supermarkets. A higher HIV prevalence was observed among men accessing incentivized mobile testing (17%) compared with nonincentivized mobile (6%) and clinic-based (10%) testing. Among mobile testers, a greater proportion of incentivized men reported being first-time testers (60 vs. 42%, P < 0.001) and had advanced disease (15 vs. 8% had CD4 <200 cells/ml, P ¼ 0.027) compared with nonincentivized testers. The same research group performed an observational study among adolescents offering incentivized testing as part of participation in multidimensional youth center activities compared with uptake of testing at a local clinic in the adjacent community. Among youth aged 12-15 years, 12.7% more individuals tested at the youth center compared with the clinic [22 & ]. A recent systematic review evaluating the effects of incentives on HIV and sexually transmitted infection testing uptake (seven studies of monetary or nonmonetary rewards, including three studies described earlier [19] [20] [21] ) all demonstrated higher uptake in the incentivized groups; the greatest effect was at nonclinic-based testing sites [23 && ].
LINKAGE TO CARE
Fewer studies have investigated how financial incentives can promote linkage to and retention in HIV care, though this is an active area of current research. The two studies which have been published related to the use of incentives for linkage to care encompass behaviors from initial HIV clinic visit through virologic suppression (Table 1) . The first study offered incentives for linkage to and retention in care and focused on HIV-infected drug users in Chennai, India [24 && ]. One hundred twenty ART-naïve and eligible individuals with recent IDU from the YR Gaitonde Centre for Substance Abuse Research were referred to government facilities for ART and randomized to incentive or control arms. Participants in the incentive arm could earn up to 15 vouchers, redeemable for groceries or household items, upon achieving prespecified targets over 12 months: one for initiating ART (US$4 voucher value, the approximate average daily wage in Chennai), 12 for attending monthly clinical/medication refill visits (US$4 voucher each), and two for achieving virologic suppression (US$4
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voucher each). Control participants were not offered incentives for treatment targets, but could win vouchers in prize bowl drawings. Incentivized participants were more likely than control participants to link to care at government clinics (82 vs. 55%), have more monthly follow-up visits (8, interquartile range 3-11 vs. 3.5, interquartile range 0-9) and initiate ART earlier. No differences, however, were observed between study arms in CD4 cell count gain or rates of virologic suppression. The authors speculate that immediate incentives may be more effective than delayed ones, and virologic suppression as an outcome may have been too remote from the daily adherence required to meet that outcome.
El-Sadr et al. [25 && ] recently presented results from the 'Enhanced Test, Link to Care, Plus Treat Approach' (HPTN 065) study, which evaluated the effect of financial incentives on linkage to HIV care and viral load suppression among over 1300 HIVinfected individuals in the Bronx borough of New York City and Washington, District of Columbia, USA. Thirty-four HIV test sites and 37 care sites were randomized to incentives vs. standard of care. Incentive sites offered coupons incentivizing linkage to care to all people who tested positive for HIV, such as gift cards redeemable at HIV care sites ($25 value for blood draws, $100 value for test results/ clinic visit); the other testing sites did not offer coupons. During the 2-year intervention, over 1000 coupons were given to individuals who tested positive for HIV at the 19 sites offering coupons and 79% of the coupons were redeemed. Although the proportion of individuals who linked to HIV care within 3 months of a positive HIV test increased over time for almost all testing sites, the study found no significant improvement comparing testing sites that offered coupons to those who did not.
The researchers also evaluated the impact of offering a $70 gift card for undetectable viral load, redeemable every 3 months, and they distributed nearly 40 000 cards to 9153 participants at the sites offering incentives. Although the proportion of patients with undetectable viral load increased at most sites over time, there was no significant increase in the proportion suppressed comparing incentive to usual care sites. A modest effect of the intervention was seen at hospital-based clinics, and at the poorest performing clinics (<65% suppression at baseline).
Two ongoing studies are investigating financially incentivizing linkage to care in sub-Saharan Africa ( Table 2 ). Each focuses on providing a bundle of services in addition to incentives, with ENGAGE4-HEALTH in Mozambique evaluating the value of an incentive added to a combination intervention.
ADHERENCE AND VIROLOGIC SUPPRESSION
Various methods to incentivize ART adherence have been studied, including voucher reinforcements, prize systems, and cash payments [18] . Galarraga et al. [18] reviewed four randomized trials of conditional economic incentives for ART adherence [26] [27] [28] [29] (Table 1 ). All measured adherence by Medication Event Monitoring System pill bottles and offered cash or voucher incentives for correct doses taken. One study specifically enrolled patients experiencing treatment failure and financially rewarded them for decreased or undetectable HIV viral load [26] . The maximum potential earnings ranged from $240 to over $1000 depending on the trial, with three using escalating rewards for achieving the target behavior on a sustained basis. All of these studies showed significant increases, in adherence, some as much as 30%, in the incentive groups compared with controls.
A recent (2013) pilot study by Farber et al. [12] enrolled men from a Veterans Administration clinic to evaluate the feasibility and preliminary efficacy of a $100 incentive for virologic suppression or a reduction in viral load. Each individual served as his own control, comparing the intervention year with the previous year using routine clinic quarterly viral load checks. Although there was no change in proportion of individuals with undetectable viral loads (76% before to 77% after the intervention), among those with prior detectable viral loads, there was an improvement in the proportion with undetectable viral loads, from 57% before to 69% (P ¼ 0.03) after the intervention.
These studies of incentivized ART adherence have all been small, and notably, the three studies that measured adherence outcomes after cessation of the incentive intervention [27] [28] [29] found that the benefits faded as early as 8 weeks later. This speaks to the difficulty of maintaining durable results for a complex behavior that requires long-term maintenance. Furthermore, these published studies have largely been carried out among US-based men, many with concurrent substance use. Fortunately, this aspect of the HIV care cascade has the greatest number of ongoing studies, including several in resource-limited settings, which should expand the knowledge base in this important area ( Table 2) .
PREVENTION
Financial incentives have also been used with success outside of the HIV treatment and care cascade, and the use of cash payments to reduce HIV risk, either by addressing structural and social vulnerabilities such as poverty or by directly incentivizing Financial incentives to improve progression through the HIV treatment cascade Bassett et al. Financial incentives to improve progression through the HIV treatment cascade Bassett et al. behavior change, has emerged as a novel HIV prevention tool. Over 1 billion people worldwide receive cash payments as part of social protection [9] . These payments may be unconditional, such as payments to households with children who earn less than a means-tested benchmark in South Africa [30] or conditional on certain behaviors such as school or preventive care attendance for impoverished households in the Oportunidades program in Mexico [31] .
In addition to improving socioeconomic status, these cash payments are believed to reduce sexual risk taking in several ways, including improving individuals' outlook for the future and increasing preferences for healthier behaviors and activities with delayed returns such as schooling [6, 8] . Cash may also address the causal path linking poverty to HIV infection by mitigating the need for transactional sex and sex with older partners and allow individuals to give more weight to long-term consequences of risk behaviors [32] . Recent studies from South Africa and Kenya highlight the impact of government-administered cash transfer programs for households with children on sexual risk behavior (Table 1) . Cluver et al.
[30] performed a prospective observational study of participants aged 10-17 randomly selected from census areas in two urban and two rural health districts in South Africa and found that receipt of a household cash transfer was associated with reduced incidence of transactional sex: in households with no grant, 5.5% of girls had transactional sex during the year, compared with 2.5% in grant households. A similar association was noted for reduced incidence of agedisparate sex for girls (4.3% among girls in households without grants compared with 1.2% in recipient households) [30] . In Kenya, Handa et al. [33 & ] found that during the initial rollout of a Kenyan national social protection program, the random allocation of $20 monthly to poor households with at least one orphan or vulnerable child reduced the relative odds of sexual debut among young people age 15-25 by 31%, with a larger impact among females (42%) than males (26%). Taken together, the Cluver and Handa studies support the association between government-administered unconditional household-level cash transfers and risk reduction, particularly for adolescent girls.
Three recent randomized trials with biomarker endpoints provide compelling evidence that conditional cash transfers can reduce sexually transmitted infections and HIV infection. De Walque et al.
[34] compared the impact of low ($10 every 4 months) and high value ($20 every 4 months) conditional cash transfers in young adults (age [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] [30] in Tanzania on the prevalence of sexually transmitted infections. At the end of 12 months, high-value participants had 27% lower sexually transmitted infection prevalence adjusted relative risk 0.73, 95% CI 0.47-0.99] compared with controls; there was no significant difference between lowvalue participants and controls. In Malawi, Baird et al.
[35] used unconditional and conditional cash transfers (between $1 and 5 monthly given to students and $4 and 10 given to parents), contingent upon school attendance, to reduce HIV risk among school girls (age [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] . The financial incentive groups had 60% lower HIV prevalence (adjusted odds ratio 0.36, 95% CI 0.14-0.91) and were more likely to stay in school.
Finally, the most recent published study to use incentives for safer sex behavior had the most robust primary outcome, HIV incidence, and potentially targeted the most at risk individuals using behavioral economics. Nyqvist et al. [36 && ] randomly assigned over 3000 young adults (age 18-32) in Lesotho to the control or one of two intervention arms eligible to receive a lottery ticket every 4 months, with a chance to win either $50 or $100 if they tested negative for two treatable sexually transmitted infections in the prior week. This lottery-style incentive led to a 21.4% reduction in HIV incidence or 3.4% lower HIV prevalence rate in intervention compared with controls after 2 years. Furthermore, risk-taking individuals (measured through a hypothetical risk aversion question) responded more forcefully to the lottery incentive. The authors note that by using a gamble for the incentive intervention, first, lotteries are relatively more attractive to people willing to take monetary risks; these may be the same people with risky sexual behavior, and second, people often overestimate small probabilities and therefore prefer a small chance at a large reward over a small certain reward.
Owing to the fact that so few published prevention studies assess HIV incidence, the final results of the CAPRISA 007 and HPTN 068 trials are eagerly awaited to provide additional evidence on conditional cash incentives for HIV prevention ( Table 2) .
CONCLUSION
Cash transfers are increasingly recognized for their potential to improve engagement in HIV care and promote safer sexual behavior. There is some evidence that incentives increase demand for HIV testing; this may be particularly useful for increasing uptake among hard-to-reach populations such as men and adolescents. Conditional incentives for linkage to care are the newest and most active area of emerging research, but an area for which there is equivocal evidence of efficacy. Several small studies have shown efficacy for improved adherence during Financial incentives to improve progression through the HIV treatment cascade Bassett et al.
the active phase of incentives, but more work is needed to understand the potential for durability beyond the period of incentives and how incentives may be used with other techniques, such as social support, to improve internal motivation and habit formation. The most evidence to date is in the area of sexual risk reduction, where there is robust evidence of spillover effects for health from social protection programs targeting poverty and education.
More work is needed to assess the efficacy of different incentive approaches. Should incentives be conditional or unconditional? Is a lottery or receipt of a certain value more effective for different populations or particular aspects of the care cascade? Are people motivated more by cash or other rewards, such as food vouchers? Should incentives be linked to measures of immediate behaviors (such as opening a pill bottle) or to measures of clinical outcomes (such as virologic suppression)? Understanding the efficacy, durability, scalability, and cost-effectiveness of these different approaches will help maximize the impact of incentives in curtailing the HIV epidemic. 
&&
Nyqvist MB, Corno L, de Walque D, Svensson J. Using lotteries to incentivize safer sexual behavior: evidence from a randomized controlled trial on HIV prevention. World Bank Policy Research Working Paper #7215; 2015. This randomized study evaluated the impact of a lottery incentive among young adults in Lesotho and found a 21% reduction in HIV incidence compared with controls after 2 years, with a large effect noted among risk-taking individuals. 37. Cluver LD, Orkin FM, Boyes ME, Sherr L. Cash plus care: social protection cumulatively mitigates HIV-risk behaviour among adolescents in South Africa. AIDS 2014; 28 (Suppl 3):S389-S397.
